No sPCMA, No Worries … We’ve Got Part D Covered

Summary

Just because we can’t meet at sPCMA doesn’t mean we can’t discuss what’s next for Medicare Part D.

Access Recording

Our experts engaged in a conversation about the outlook for the Part D program and issues to watch during the 2021 bid/contracting cycle and beyond. Our panelists explored the potential implications of a preferred specialty tier on 2021 and 2022 formularies, the future of Part D benefit redesign, and some key impacts across different types of Part D plans.

Our panelists also answered questions from the audience.

Panelists

Moderator

Kelly Brantley , Practice Director, Policy

Kelly Brantley co-leads Avalere’s Policy practice, advising life sciences companies, health plans, patient organizations, and other partners on how to shape and navigate the dynamic health policy environment.

Speaker

Miryam Frieder , Practice Director, Policy

Miryam Frieder leads Avalere’s Policy practice, advising a wide range of clients on Medicare Part D and the drug pricing policy environment.

Speaker

Michael Schneider , Principal

Mike Schneider is an experienced health care executive with over 20 years of experience in pharmaceutical manufacturer, pharmacy benefit manager, and payer side of health care.